CD8A and neoplasm: Anti-CTLA4 works at the T cell–APC immune synapse by promoting the unopposed interaction of B7 costimulatory ligands with CD28, thereby enhancing the activation of CD4+ and CD8+ T cells and rebalancing the regulatory compartments within the tumor microenvironment (TME) [37].